Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.

Next Previous
Trial Profile

Multi-Center, Randomized, Double-Blind, Placebo and Active-Controlled, 6-week Study to Evaluate the Safety, Tolerability and Pharmacodynamic Activity of Inhaled TPI 1020 in COPD Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2012

At a glance

  • Drugs TPI 1020 (Primary) ; Budesonide
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 04 Mar 2009 Company (Pharmaxis) added to the associations field as reported by as reported by ClinicalTrials.gov.
    • 04 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 23 Dec 2008 Results reported in a Topigen Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top